<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03908372</url>
  </required_header>
  <id_info>
    <org_study_id>NCC1950</org_study_id>
    <nct_id>NCT03908372</nct_id>
  </id_info>
  <brief_title>Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Randomized Multicenter Phase II/III Study of Optimized Treatment Strategies for Stage II and III Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to optimize treatment strategies for patients with stage II and
      III nasopharyngeal carcinoma, reduce the side effects related to treatment and improve the
      quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The data came from conventional studies showed that the distant metastases and toxicities
      associated with concurrent chemoradiotherapy were main problems for patients with clinical
      stage II and III nasopharyngeal carcinoma. However, inductive chemotherapy can decrease the
      likelihood of emergence of distant metastasis and reduce treatment related toxicities as
      previous studies showed.

      The role of inductive chemotherapy in screening low-risk nasopharyngeal carcinoma for less
      treatment intensity is under-evaluated in the era of intensity-modulated radiotherapy (IMRT).
      we hope to find the optimized treatment strategies by reducing the intensity of treatment
      according to the treatment response of inductive chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2019</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progress free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local-regional control</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete response</measure>
    <time_frame>13 weeks</time_frame>
    <description>efficacy will be measured by RECIST1.1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Stage II, III</condition>
  <condition>Nasopharyngeal Squamous Cell Carcinoma</condition>
  <condition>Induction Chemotheray</condition>
  <condition>Concurrent Chemoradiotherapy</condition>
  <condition>Reduce Treatment Intensity</condition>
  <arm_group>
    <arm_group_label>Induction chemotherapy(IC)+IMRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemotherapy for two cycles, the patients with complete response will receive 60 Gy to the gross target volume of nasopharynx, partial response 64 Gy, and the absence of response will receive concurrent chemoradiotherapy as the same as CCRT arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concurrent chemoradiotherapy(CCRT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cisplatin 100mg/m2 IV on d1 of each 21 days for two cycles at least and 70 Gy radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Induction CT: Docetaxel 75mg/m2 IV on d1, every 21 days for two cycles</description>
    <arm_group_label>Induction chemotherapy(IC)+IMRT</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Induction chemotherapy:cisplatin 75mg/m2 IV on d1,every 21 days for two cycles.Concurrent chemoradiotherapy:cisplatin 100mg/m2 IV on d1 of each 21 days for at least two cycles during 70 Gy radiotherapy</description>
    <arm_group_label>Concurrent chemoradiotherapy(CCRT)</arm_group_label>
    <arm_group_label>Induction chemotherapy(IC)+IMRT</arm_group_label>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>IC+IMRT arm:the patients with complete response will receive 60Gy to the gross target volume of nasopharynx, partial response 64Gy, and the absence of response or stable will receive 70Gy. CCRT arm: 70Gy to the gross target volume of nasopharynx.</description>
    <arm_group_label>Concurrent chemoradiotherapy(CCRT)</arm_group_label>
    <arm_group_label>Induction chemotherapy(IC)+IMRT</arm_group_label>
    <other_name>intensity-modulated radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathology confirmed nasopharyngeal squamous cell carcinoma.

          -  Aged 18 to 70 years old;

          -  Stage II-III (T1N1M0，T2-3N0-1M0) diseases according to 8th AJCC Staging and the
             shortest diameter of the largest lymph node involved is no more than 3cm;

          -  KPS≥70;

          -  Have measurable lesions on CT/MRI before treatment;

          -  Treatment for the first time;

          -  At least 6 months lifetime was expected;

          -  Adequate laboratory indexes, defined as follows: Hemoglobin &gt; 120g/L, WBC &gt;
             4.0x10*9/L, Plt &gt; 100x10*9/L &lt; 2, all indexes of liver and kidney function ≤ 1.25
             times of the institutional upper limit of normal value, no hearing loss;

          -  Can understand and sign the consent

          -  Have follow up condition

        Exclusion Criteria:

          -  Past malignancies history (except for stage I non-melanoma skin cancer or cervical
             carcinoma in situ)

          -  Previously treatment for cancer

          -  Pregnant or breeding woman, female without contraception

          -  Enrolling in other drug trials

          -  Severe comorbidities including myocardial infarction, arrhythmia, cerebral vascular
             disease, ulceration disease, mental disease and uncontrolled diabetes

          -  Without follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junlin Yi, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junlin Yi, M.D</last_name>
    <phone>008601366121799</phone>
    <email>junlinyi@sohu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijin</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junlin yi, MD</last_name>
      <phone>0086013661217998</phone>
      <email>yijunlin1969@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Xu C, Sun R, Tang LL, Chen L, Li WF, Mao YP, Zhou GQ, Guo R, Lin AH, Sun Y, Ma J, Hu WH. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis. Oral Oncol. 2018 Mar;78:37-45. doi: 10.1016/j.oraloncology.2018.01.008. Epub 2018 Feb 20.</citation>
    <PMID>29496056</PMID>
  </reference>
  <reference>
    <citation>Liu YC, Wang WY, Twu CW, Jiang RS, Liang KL, Lin PJ, Lin JW, Lin JC. Comparison Long-term Outcome of Definitive Radiotherapy plus Different Chemotherapy Schedules in Patients with Advanced Nasopharyngeal Carcinoma. Sci Rep. 2018 Jan 11;8(1):470. doi: 10.1038/s41598-017-18713-z.</citation>
    <PMID>29323141</PMID>
  </reference>
  <reference>
    <citation>Yao JJ, Yu XL, Zhang F, Zhang WJ, Zhou GQ, Tang LL, Mao YP, Chen L, Ma J, Sun Y. Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis. Chin J Cancer. 2017 Mar 6;36(1):26. doi: 10.1186/s40880-017-0195-6.</citation>
    <PMID>28264724</PMID>
  </reference>
  <reference>
    <citation>Xu C, Zhang LH, Chen YP, Liu X, Zhou GQ, Lin AH, Sun Y, Ma J. Chemoradiotherapy Versus Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: A Systemic Review and Meta-analysis of 2138 Patients. J Cancer. 2017 Jan 15;8(2):287-297. doi: 10.7150/jca.17317. eCollection 2017.</citation>
    <PMID>28243333</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 31, 2019</study_first_submitted>
  <study_first_submitted_qc>April 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2019</study_first_posted>
  <last_update_submitted>April 7, 2019</last_update_submitted>
  <last_update_submitted_qc>April 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Li Gao</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

